Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the surgical infection society and the infectious diseases society of america

Clinical Infectious Diseases

Volumn 50, Issue 2, 2010, Pages 133-164

  Solomkin, Joseph S ^a   Mazuski, John E ^b   Bradley, John S ^c   Rodvold, Keith A ^f   Goldstein, Ellie J C ^d   Baron, Ellen J ^e   O'Neill, Patrick J ^g   Chow, Anthony W ⁿ   Patchen Dellinger, E ^h   Eachempati, Soumitra R ⁱ   Gorbach, Sherwood ^j   Hilfiker, Mary ^c   May, Addison K ^k   Nathens, Avery B ^o   Sawyer, Robert G ^l   Bartlett, John G ^m  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g MARICOPA MEDICAL CENTER   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ WEILL CORNELL MEDICAL CENTER   (United States)

^j TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF VIRGINIA   (United States)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^o ST MICHAEL'S HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIFUNGAL AGENT; AZTREONAM; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; DORIPENEM; ERTAPENEM; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABSCESS DRAINAGE; ACUTE APPENDICITIS; ADD ON THERAPY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; APPENDICITIS; BACTERIUM CULTURE; BILIARY TRACT INFECTION; BLOOD CULTURE; CANDIDA; CANDIDIASIS; CHOLANGITIS; CHOLECYSTITIS; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG MONITORING; DRUG TREATMENT FAILURE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; EVIDENCE BASED PRACTICE; FLUID RESUSCITATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM STAINING; HIGH RISK PATIENT; HOSPITALIZED CHILD; HUMAN; INFECTION COMPLICATION; INFECTION CONTROL; INFECTION RISK; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; NECROTIZING ENTEROCOLITIS; NONHUMAN; OUTPATIENT; PATIENT CARE; PATIENT MOBILITY; PERITONITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; TREATMENT DURATION;

ABDOMEN; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 73649114948     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649554     Document Type: Review

References (190)

1. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults [see comments]. Chest 1991;100:1619-1636
2. Le Gall JR, Lemcshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-2963 (erratum: JAMA 1994;271:1321).
3. Lemeshow S, Le Gall JR. Modeling the severity of illness of ICU patients: a systems update. JAMA 1994;272:1049-1055 (Pubitemid 24294657)
4. Meyer AA, Messick WJ, Young P, et al. Prospective comparison of clinical judgment and APACHE II score in predicting the outcome in critically ill surgical patients. J Trauma 1992; 32:747-753
5. Swenson BR, Metzger R, Hedrick TL, et al. Choosing antibiotics for intra-abdominal infections: what do we mean by "high risk"? Surg Infect (Larchmt) 2009; 10:29-39.
6. DeFrances CJ, Cullen KA, Kozak LJ. National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 2007;165:1-209.
7. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995;274:968-974
8. Field M, Lohr K. Clinical practice guidelines: directions for a new program. In: Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines. Washington, DC: National Academy Press, 1990:8.
9. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997-1005.
10. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. 3rd edition. Surgical Infection Society, 2002:161-174
11. The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979;121:1193-1254
12. Wagner JM, McKinney WP, Carpenter JL. Does this patient have appendicitis? JAMA 1996;276:1589-1594
13. Bundy DG, Byerley JS, Liles EA, Perrin EM, Katznelson J, Rice HE. Does this child have appendicitis? JAMA 2007;298:438-451
14. Silen WW. Cope's early diagnosis of the acute abdomen. 12th ed. New York: Oxford University Press, 2005.
15. Alvarado A. A practical score for the early diagnosis of acute appendicitis. Ann Emcrg Med 1986; 15:557-564 (Pubitemid 16052109)
16. Pinto LN, Pereira JM, Cunha R, Pinto P, Sirlin C. CT evaluation of appendicitis and its complications: imaging techniques and key diagnostic findings. AJR Am J Roentgenol 2005; 185:406-417
17. Urban BA, Fishman EK. Targeted helical CT of the acute abdomen: appendicitis, diverticulitis, and small bowel obstruction. Semin Ultrasound CT MR 2000;21:20-39. (Pubitemid 30090678)
18. Doria AS, Moineddin R, Kellenberger CJ, et al. US or CT for diagnosis of appendicitis in children and adults? A meta-analysis. Radiology 2006;241:83-94. (Pubitemid 44433338)
19. Mariak Z, White MD, Lewko J, Lyson T, Piekarski P. Direct cooling of the human brain by heat loss from the upper respiratory tract. J Appl Physiol 1999;87:1609-1613
20. White MD. Components and mechanisms of thermal hyperpnea. J Appl Physiol 2006; 101:655-663
21. Barnes BA, Behringer GE, Wheelock FC, Wilkins EW. Treatment of appendicitis at the Massachusetts General Hospital (1937-1959). JAMA 1962; 180:122-126
22. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shod« 2008. Crit Care Med 2008;36:296-327.
23. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-1596 (Pubitemid 43810035)
24. van Nieuwenhoven CA, Buskens E, van Tiel FH, Bonten MJ. Relationship between methodological trial quality and the effects of selective digestive decontamination on pneumonia and mortality in critically ill patients. JAMA 2001;286:335-340 (Pubitemid 32656164)
25. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 2005; 189:395-404. (Pubitemid 40488232)
26. Bratzler DW, Hunt DR. The surgical infection prevention and surgical care improvement projects: national, initiatives to improve outcomes for patients having surgery. Clin Infect Dis 2006; 43:322-330
27. Marshall JC, Maier RV, Jimenez M, Dellinger EP. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004;32(Suppl 11):S513-26.
28. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584-599 (Pubitemid 127774277)
29. Koperna T, Schulz F. Prognosis and treatment of peritonitis. Do we need new scoring systems? Arch Surg 1996; 131:180-186
30. Koperna T, Schulz F. Relaparotomy in peritonitis: prognosis and treatment of patients with persisting intraabdominal infection. World J Surg 2000;24:32-37
31. Mulier S, Penninckx F, Verwaest C, et al. Factors affecting mortality in generalized postoperative peritonitis: multivariate analysis in 96 patients. World J Surg 2003;27:379-384 (Pubitemid 36920106)
32. Grunau G, Heemken R, Hau T. Predictors of outcome in patients with postoperative intra-abdominal infection. Eur J Surg 1996; 162:619-625 (Pubitemid 126439773)
33. Betsch A, Wiskirchen J, Trubenbach J, et al. CT-guided percutaneous drainage of intra-abdominal abscesses: APACHE III score stratification of 1-year results. Eur Radiol 2002; 12:2883-2889 (Pubitemid 36940407)
34. Bufakri A, Giustozzi G, Moggi L. Postoperative intraabdominal abscesses: percutaneous versus surgical treatment. Acta Chir Belg 1996; 96:197-200. (Pubitemid 126483768)
35. Theisen J, Bartels H, Weiss W, Berger H, Stein HJ, Siewert JR. Current concepts of percutaneous abscess drainage in postoperative retention. J Gastrointest Surg 2005;9:280-283 (Pubitemid 40202987)
36. Pruett TL, Simmons RL. Status of percutaneous catheter drainage of absceses. Surg Clin North Am 1988;68:89-105. (Pubitemid 18070940)
37. Gcrzof SG, Robbins AH, Birkett DH. Computed tomography in the diagnosis and management of abdominal abscesses. Gastrointest Radiol 1978;3:287-294 (Pubitemid 9208146)
38. Gcrzof SG, Johnson WC, Robbins AH, Nabseth DC. Expanded criteria for percutaneous abscess drainage. Arch Surg 1985;120:227-232 (Pubitemid 15170597)
39. Gerzof SG, Robbins AH, Johnson WC, Birkett DH, Nabseth DC. Percutaneous catheter drainage of abdominal abscesses: a five-year experience. N Engl J Med 1981;305:653-657
40. vanSonnenberg E, Mueller PR, Ferrucci JT Jr. Percutaneous drainage of 250 abdominal abscesses and fluid collections. Part I: results, failures, and complications. Radiology 1984; 151:337-341
41. Levison MA. Percutaneous versus open operative drainage of intraabdominal abscesses. Infect Dis Clin North Am 1992;6:525-544
42. Sones PJ. Percutaneous drainage of abdominal abscesses. AJR Am J Roentgenol 1984; 142:35-39
43. Maher MM, Gervais DA, Kalra MK, et al. The inaccessible or undrainable abscess: how to drain it. Radiographics 2004;24:717-735
44. van Ruler O, Mahler CW, Boer KR, et al. Comparison of on-demand vs planned relaparotomy strategy in patients with severe peritonitis: a randomized trial. JAMA 2007;298:865-872
45. Schein M, Paladugu R. Planned relaparotomies and laparostomy. In: Schein M, Marshall JC, eds. Source control: a guide to the management of surgical infections. Berlin: Springer-Verlag, 2003:412-423
46. Cueto J, D'Allemagne B, Vazquez-Frias JA, et al. Morbidity of laparoscopic surgery for complicated appendicitis: an international study. Surg Endose 2006;20:717-720 (Pubitemid 43978766)
47. Akinci D, Akhan O, Ozmen MN, et al. Percutaneous drainage of 300 intraperitoneal abscesses with long-term follow-up. Cardiovasc Intervent Radiol 2005;28:744-750 (Pubitemid 41586852)
48. De Waele JJ, Hoste EA, Blot SI. Blood stream infections of abdominal origin in the intensive care unit: characteristics and determinants of death. Surg Infect (Larchmt) 2008;9:171-177
49. Rashid RM, Salah W, Parada JP. 'Streptococcus milleri' aortic valve endocarditis and hepatic abscess. J Med Microbiol 2007; 56:280-2.
50. Dougherty SH. Antimicrobial culture and susceptibility testing has little value for routine management of secondary bacterial peritonitis. Clin Infect Dis 1997;25(Suppl 2):S258-61.
51. Kokoska ER, Silen ML, Tracy TF Jr, et al. The impact of intraoperative culture on treatment and outcome in children with perforated appendicitis. J Pediatr Surg 1999;34:749-753
52. 52. Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM.. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996;23:486-494 (Pubitemid 26304496)
53. Aldridge KE, O'Brien M. In vitro susceptibilities of the Bacteroides fragilis group species: change in isolation rates significantly affects overall susceptibility data. J Clin Microbiol 2002;40:4349-4352
54. Cuchural GJ Jr, Tally FP, Jacobus NV, et al. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother 1988;32:717-722
55. Snydman DR, McDermott L, Cuchural GJ Jr, et al. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994. Clin Infect Dis 1996; 23(Suppl l):S54-65.
56. Snydman DR, Jacobus NV, McDermott LA, et al. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother 1999;43:2417-2422
57. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997-2000. Clin Infect Dis 2002;35(Suppl l):S126-34.
58. Golan Y, McDermott LA, Jacobus NV, et al. Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother 2003;52:208-213
59. Goldstein EJ, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez H. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006;50:148-155
60. Snydman DR, Jacobus NV, McDermott LA, et al. In vitro activities of newer quinolones against bacteroides group organisms. Antimicrob Agents Chemother 2002;46:3276-3279
61. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007;51:1649-1655
62. 62. Borbeau PJ, Riley J, Heiter BJ, Master R, Young C, Pierson C. Use of the BacT/Alert blood culture system for culture of sterile body fluids other than blood. J Clin Microbiol 1998;36:3273-3277 (Pubitemid 28476178)
63. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated, from patients with intraabdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55:965-973
64. Yellin AE, Heseltine PN, Berne TV, et al. The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 1985;161:303-307
65. Bradley JS, Behrendt CE, Arrieta AC, et al. Convalescent phase outpatient parenteral antiinfective therapy for children with complicated appendicitis. Pediatr Infect Dis J 2001;20:19-24.
66. Lin WJ, Lo WT, Chu CC, Chu ML, Wang CC. Bacteriology and antibiotic susceptibility of community-acquired intra-abdominal infection in children. J Microbiol Immunol Infect 2006;39:249-254
67. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991;214:543-549
68. 68. Maltezou HC, Nikolaidis P, Lebesii E, Dimitriou L, Androulakakis E, Kafetzis DA. Piperacillin/tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2001;20:643-646 (Pubitemid 32953836)
69. 69. Angeras MH, Darle N, Hamnstrom K, et al. A comparison of imipenem/ cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. Scand J Infect Dis 1996; 28: 513-518 (Pubitemid 26393597)
70. Luke M., Iversen J, Sondergaard J, et al. Ceftriaxone/metronidazole is more effective than ampicillin/netilmidn/metronidazole in the treatment of bacterial peritonitis. Eur J Surg 1991; 157:397-401.
71. Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenemcilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. Arch Surg 1997; 132: 1294-1302
72. 72. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 1996; 223:303-315 (Pubitemid 126437689)
73. 73. Alio MD, Bennion RS, Kathir K, et al. Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis. Am. Surg 1999;65:99-104. (Pubitemid 29059328)
74. Meiler JL, Reyes HM, Loeff DS, Federer L, Hall JR. One-drug versus two-drug antibiotic therapy in pediatric perforated appendicitis: a prospective randomized study. Surgery 1991;4:764-767
75. 75. Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [study ID numbers: 3074A1-301-WW; ClinicalTrials.gov identifier: NCT00081744], BMC Infect Dis 2005; 5:88. (Pubitemid 41582039)
76. 76. Namias N, Solomkin JS, Jensen EH, Tomassini JE, Abramson MA. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect (Larchmt) 2007;8:15-28. (Pubitemid 46598292)
77. Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003;237:235-245
78. 78. Malangoni MA, Song J, Herrington J, Choudhri S, Pertel P. Randomized controlled trial of moxifloxacin compared with pipcracillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006;244:204-211 (Pubitemid 44305534)
79. Bieluch VM, Cuchural GJ, Snydman DR, Gorbach SL, Tally FP. Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates. Diagn Microbiol Infect Dis 1987;7:119-126
80. Snydman DR, Cuchural GJ Jr, McDermott L, Gill M. Correlation of various in vitro testing methods with, clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis. Antimicrob Agents Chemother 1992; 36:540-544
81. 81. Oh H, Nord CE, Barkholt L, Hedberg M, Edlund C. Ecological disturbances in intestinal microflora caused, by clinafloxacin, an extendedspectrum quinolone. Infection 2000; 28:272-277 (Pubitemid 30776371)
82. 82. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1: 101-114 (Pubitemid 33586045)
83. Cohn SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/ oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000;232:254-262
84. 84. Ohlin B, Cederberg A, Forssell H, Solhaug JH, Tveit E. Piperacillin/ tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections. Eur J Surg 1999;165:875-884 (Pubitemid 29459710)
85. 85. Polk HC Jr, Fink MP, Laverdiere M, et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group. Am Surg 1993;59:598-605. (Pubitemid 23265592)
86. Sirinek KR, Levine BA. A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. Surg Gynecol Obstet 1991; 172(Suppl):30-35
87. Walker AP, Nichols RL, Wilson RF, et al. Efficacy of a β-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 1993;217:115-121
88. 88. Brook I, Frazier EH. Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis. J Med Microbiol 2000;49:827-830 (Pubitemid 30666635)
89. Christou NV, Barie PS, Dellinger EP, Waymack JP, Stone HH. Surgical Infection Society intra-abdominal infection study: prospective evaluation of management techniques and outcome. Arch Surg 1993; 128: 193-8; discussion:198-199
90. Dellinger EP, Wertz MJ, Meakins JL, et al. Surgical infection stratification system for intra-abdominal infection: multicenter trial.. Arch Surg 1985;120:21-9.
91. Nystrom PO, Bax R, Dellinger EP, et al. Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. Joint Working Party of SIS North America and Europe. World J Surg 1990;14:148-158
92. 92. Ohmann C. Prognostic scores and design of clinical studies. Infection 1998;26:342-344 (Pubitemid 28466519)
93. Ohmann C, Wittmann DH, Wacha H. Prospective evaluation of prognostic scoring systems in peritonitis. Peritonitis Study Group. Eur J Surg 1993;159:267-274
94. 94. Wacha H, Hau T, Dittmer R, Ohmann C. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg 1999; 384:24-32. (Pubitemid 29225314)
95. Bailey JA, Virgo KS, DiPiro JT, Nathens AB, Sawyer RG, Mazuski JE. Aminoglycosides for intra-abdominal infection: equal to the challenge? Surg Infect (Larchmt) 2002;3:315-335
96. 96. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007;45:753-760 (Pubitemid 47378891)
97. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763-1771
98. Montravers P, Dupont H, Gauzit R, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34:646-652
99. Montravers P, Lepape A, Dubreuil L, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009; 63:785-794
100. 100. Montravers P, Chalfine A, Gauzit R, et al. Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections. Ann Surg 2004;239:409-416 (Pubitemid 38229072)
101. 101. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155 (Pubitemid 30485502)
102. 102. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474 (Pubitemid 29083057)
103. Lodise TP Jr, Patel N, Kwa A, et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007;51:3510-3515
104. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-189
105. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989;2:1437-1440
106. Solomkin JS, Flohr AB, Quie PG, Simmons RL. The role of Candida in intraperitoneal infections. Surgery 1980; 88:524-530
107. 107. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high- risk surgical patients. Crit Care Med 1999;27:1066-1072 (Pubitemid 29314312)
108. Mean M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 2008; 12:204.
109. 109. Hof H. Developments in the epidemiolgy of invasive fungal infections- implications for the empiric and targeted antifungal therapy. Mycoses 2008;51(Suppl 1):1-6. (Pubitemid 351678030)
110. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008;46:150-156
111. Pfaller MA, Messer SA, Boyken L, et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical, isolates of Candida spp. tested by dinical and laboratory standards institute-recommended broth microdilution methods. J Clin Microbiol 2007;45:70-75
112. 112. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029 (Pubitemid 35461658)
113. 113. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472-2482 (Pubitemid 46919773)
114. 114. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-893 (Pubitemid 47580382)
115. 115. Blot S, De Waele JJ. Critical issues in the dinical management of complicated intra-abdominal infections. Drugs 2005;65:1611-1620 (Pubitemid 41138984)
116. Burnett RJ, Haverstock DC, Dellinger EP, et al. Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 1995;118:716-721
117. 117. Sitges-Serra A, Lopez MJ, Girvent M, Almirall S, Sancho JJ. Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 2002; 89:361-367 (Pubitemid 34227039)
118. Mascini EM, Bonten MJ. Vancomydn-resistant enterococd: consequences for therapy and infection control. Clin Microbiol Infect 2005;11(Suppl 4):43-56.
119. Leavis HL, Willems RJ, Top J, et al. Epidemic and nonepidemic multidrug-resistant Enterococcus faecium. Emerg Infect Dis 2003; 9:1108-1115
120. Bonten MJ, Willems R, Weinstein RA. Vancomydn-resistant enterococd: why are they here, and where do they come from? Lancet Infect Dis 2001; 1:314-325
121. Mazuski JE. Vancomydn-resistant enterococcus: risk factors, surveillance, infections, and treatment. Surg Infect (Larchmt) 2008;9:567-571
122. Fierobe L, Deere D, Muller C, et al. Methicillin-resistant Staphylococcus aureus as a causative agent of postoperative intra-abdominal infection: relation to nasal colonization. Clin Infect Dis 1999;29:1231-1238
123. Patel M, Kumar RA, Stamm AM, Hoesley CJ, Moser SA, Waites KB. USA300 genotype community-associated methicillin-resistant Staphylococcus aureus as a cause of surgical site infections. J Clin Microbiol 2007;45:3431-3433
124. Hirota M, Takada T, Kawarada Y, et al. Diagnostic criteria and severity
125. assessment of acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007; 14:78-82.
126. 125. Yoshida M, Takada T, Kawarada Y, et al. Antimicrobial therapy for acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007; 14: 83-90. (Pubitemid 46189146)
127. 126. Takada T, Kawarada Y, Nimura Y, et al. Background: Tokyo Guidelines for the management of acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Surg 2007; 14:1-10. (Pubitemid 46189136)
128. 127. Mayumi T, Takada T, Kawarada Y, et al. Results of the Tokyo Consensus Meeting Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007; 14: 114-121 (Pubitemid 46189149)
129. Strasberg SM. Clinical practice. Acute calculous cholecystitis. N Engl J Med 2008;358:2804-2811
130. Ralls PW, Colletti PM, Lapin SA, et al. Real-time sonography in suspected acute cholecystitis: prospective evaluation of primary and secondary signs. Radiology 1985; 155:767-771
131. Goldin AB, Sawin RS, Garrison MM, Zerr DM, Christakis DA. Aminoglycoside-based triple-antibiotic therapy versus monotherapy for children with ruptured appendidtis. Pediatrics 2007;119:905-911
132. St Peter SD, Little DC, Calkins CM, et al. A simple and more costeffective antibiotic regimen for perforated appendicitis. J Pediatr Surg 2006;41:1020-1024
133. 132. Rodriguez JC, Buckner D, Schoenike S, Gomez-Marin O, Oitidca C, Thompson WR. Comparison of two antibiotic regimens in the treatment of perforated appendicitis in pediatric patients. Int J Clin Pharmacol Ther 2000; 38:492-499 (Pubitemid 30765594)
134. 133. Nadler EP, Reblock KK, Ford HR, Gaines BA. Monotherapy versus multi-drug therapy for the treatment of perforated appendicitis in children. Surg Infect (Larchmt) 2003;4:327-333 (Pubitemid 38195782)
135. 134. St Peter SD, Tsao K, Spilde TL, et al. Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomized trial. J Pediatr Surg 2008;43:981-985 (Pubitemid 351814893)
136. Sanchez AR, Rogers RS III, Sheridan PJ. Tetracycline and other tetracydine-derivative staining of the teeth and oral cavity. Int J Dermatol 2004;43:709-715
137. Schaad UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin North Am 2005; 19:617-628
138. 137. Rice HE, Brown RL, Gollin G, et al. Results of a pilot trial comparing prolonged intravenous antibiotics with sequential intravenous/oral antibiotics for children with perforated appendicitis. Arch Surg 2001; 136: 1391-1395 (Pubitemid 33117046)
139. 138. Thompson AM, Bizzarro MJ. Necrotizing enterocolitis in newborns: pathogenesis, prevention and management. Drugs 2008;68:1227-1238 (Pubitemid 351822112)
140. Nankervis CA, Giannone PJ, Reber KM. The neonatal intestinal vasculature: contributing factors to necrotizing enterocolitis. Semin Perinatal 2008;32:83-91.
141. Plan M, Daneman A, Navarro OM, et al. Necrotizing enterocolitis: review of state-of-the-art imaging findings with pathologic correlation. Radiographics 2007;27:285-305.
142. Hunter CJ, Chokshi N, Ford HR. Evidence vs experience in the surgical management of necrotizing enterocolitis and focal intestinal perforation. J Perinatal 2008;28(Suppl l):S14-7.
143. Henry MC, Moss RL. Neonatal necrotizing enterocolitis. Semin Pediatr Surg 2008; 17:98-109.
144. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2:289-300.
145. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extendedinfusion dosing strategy. Clin Infect Dis 2007;44:357-63.
146. Edmiston CE, Krepel C, Kelly H, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Surgery 2004; 136:738-47.
147. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007;27:1081-91.
148. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009-1034
149. 148. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006;45:755-773 (Pubitemid 44182274)
150. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999;36:353-373
151. Sprandel KA, Drusano GL, Hecht DW, Rotschafer JC, Danziger LH, Rodvold KA. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagn Microbiol Infect Dis 2006;55:303-309
152. Lau AH, Emmons K, Seligsohn R. Pharmacokinetics of intravenous metronidazole at different dosages in healthy subjects. Int J Clin. Pharmacol Ther Toxicol 1991;29:386-390
153. 152. Ljungberg B, Nilsson-Ehle I, Ursing B. Metronidazole: pharmacokinetic observations in severely ill patients. J Antimicrob Chemother 1984; 14: 275-283 (Pubitemid 15147142)
154. Berne TV, Yellin AW, Appleman MD, Heseltine PN. Antibiotic management of surgically treated gangrenous or perforated appendicitis: comparison, of gentamicin and clindamycin versus cefemandole versus cefoperazone. Am. J Surg 1982;144:8-13.
155. Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990;212:581-591
156. 155. Falagas ME, Barefoot L, Griffith J, Ruthazar R, Snydman DR. Risk factors leading to dinical failure in the treatment of intra- abdominal or skin/ soft tissue infections. Eur J Clin Microbiol Infect Dis 1996; 15:913-921 (Pubitemid 27060990)
157. 156. Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004;23:682-687 (Pubitemid 39304322)
158. 157. Sturkenboom MC, Goettsch WG, Picelli G, et al. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol 2005;60:438-443 (Pubitemid 41428476)
159. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl l):S12-8.
160. 159. Wilton P, Smith R, Coast J, Millar M. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and costeffectiveness. J Health Serv Res Policy 2002;7:111-117 (Pubitemid 34984017)
161. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. 3rd ed. Surgical Infection Society, 2002: 175-234.
162. Hedrick TL, Evans HL, Smith RL, et al. Can we define the ideal duration of antibiotic therapy? Surg Infect (Larchmt) 2006;7:419-432
163. Lennard ES, Dellinger EP, Wertz MJ, Minshew BH. Implications of leukocytosis and fever at condusion of antibiotic therapy for intraabdominal sepsis. Ann Surg 1982; 195:19-24.
164. 163. de Vries AC, Besselink MG, Buskens E, et al. Randomized controlled trials of antibiotic prophylaxis in severe acute pancreatitis: relationship between methodological quality and outcome. Pancreatology 2007; 7: 531-538 (Pubitemid 47587633)
165. Solomkin JS, Dellinger EP, Bohnen JM, Rostein OD. The role of oral antimicrobials for the management of intra-abdominal infections. New Horiz 1998;6(Suppl 2):S46-52.
166. 165. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 1996; 223:303-315 (Pubitemid 126437689)
167. 166. Smink DS, Finkelstein JA, Garcia Pena BM, Shannon MW, Taylor GA, Fishman SJ. Diagnosis of acute appendicitis in children using a dinical practice guideline. J Pediatr Surg 2004; 39:458-463 (Pubitemid 38338367)
168. Schneider C, Kharbanda A, Bachur R. Evaluating appendicitis scoring systems using a prospective pediatric cohort. Ann Emerg Med 2007; 49:778-784
169. Emil S, Taylor M, Ndiforchu F, Nguyen N. What are the true advantages of a pediatric appendicitis clinical pathway? Am Surg 2006; 72:885-889
170. Paulson EK, Kalady MF, Pappas TN. Clinical practice: suspected appendicitis. N Engl J Med 2003;348:236-242
171. 170. Yu J, Fulcher AS, Turner MA, Halvorsen RA. Helical CT evaluation of acute right lower quadrant pain: part II, uncommon mimics of appendicitis. AJR Am J Roentgenol 2005; 184:1143-1149 (Pubitemid 43821888)
172. 171. Yu J, Fulcher AS, Turner MA, Halvorsen RA. Helical CT evaluation of acute right lower quadrant pain: part I, common mimics of appendicitis. AJR Am J Roentgenol 2005; 184:1136-1142 (Pubitemid 43821887)
173. National Center for Health Statistics. Ambulatory and Inpatient Procedures in the United States, 1996. National Center for Health Statistics, 2004.
174. 173. Styrud J, Eriksson S, Nilsson I, et al. Appendectomy versus antibiotic treatment in acute appendicitis, a prospective multicenter randomized controlled trial. World J Surg 2006;30:1033-1037 (Pubitemid 43824415)
175. 174. Taylor M, Emil S, Nguyen N, Ndiforchu F. Emergent vs urgent appendectomy in children: a study of outcomes. J Pediatr Surg 2005; 40: 1912-1915 (Pubitemid 41774177)
176. Ditillo MF Dziura JD, Rabinovic R. Is it safe to delay appendectomy in adults with acute appendicitis? Ann Surg 2006; 244:656-660
177. 176. Bagi P, Dueholm S. Nonoperative management of the ultrasonically evaluated appendiceal mass. Surgery 1987; 101:602-605 (Pubitemid 17076099)
178. 177. Hoffmann J, Lindhard A, Jensen HE. Appendix mass: conservative management without interval appendectomy. Am J Surg 1984; 148:379-382 (Pubitemid 14037310)
179. Jeffrey RB Jr, Federle MP, Tolentino CS. Periappendiceal inflammatory masses: CT-directed management and dinical outcome in 70 patients. Radiology 1988;167:13-16
180. Lewin J, Fenyo G, Engstrom L. Treatment of appendiceal abscess. Acta Chir Scand 1988; 154:123-125
181. 180. Samuel M, Hosic G, Holmes K. Prospective evaluation of nonsurgical versus surgical management of appendiceal mass. J Pediatr Surg 2002;37: 882-886 (Pubitemid 34575799)
182. Hogan MJ. Appendiceal abscess drainage. Tech Vase Interv Radiol 2003;6:205-214
183. 182. Andersson RE, Petzold MG. Nonsurgical treatment of appendiceal abscess or phlegmon: a systematic review and meta-analysis. Ann Surg 2007;246:741-748 (Pubitemid 350035649)
184. Corfield L. Interval appendicectomy after appendiceal mass or abscess in. adults: what is "best practice"? Surg Today 2007;37:1-4.
185. 184. Kaminski A, Liu IL, Applebaum H, Lee SL, Haigh PI. Routine interval appendectomy is not justified after initial, nonoperative treatment of acute appendicitis. Arch Surg 2005;140:897-901. (Pubitemid 41345987)
186. Andersen BR, Kallehave FL, Andersen HK. Antibiotics versus placebo for prevention of postoperative infection after appendicectomy. Cochrane Database Syst Rev 2005;3:CD001439.
187. Taketomo CK, Hodding JH, Kraus DM, eds. Pediatric dosage handbook. 14th ed. Hudson, OH: Lexi-Comp, 2007.
188. Bradley JS, Sauberan J. Antimicrobial agents: principles and practice of pediatric infectious diseases. 3rd ed. Philadelphia: Churchill Livingstone, 2008.
189. Sauberan J. Systemic anti-infectives. Nelson's pocket book of pediatric antimicrobial therapy. 16th ed. Buenos Aires: ACINES, 2006.
190. 189. Solomkin JS, Wilson SE, Christou NV, et al. Results of a clinical trial of dinafloxadn versus imipenem/cilastatin for intraabdominal infections. Ann Surg 2001;233:79-87. (Pubitemid 32043607)